- Home
- XERS vs LINC Comparison
XERS vs LINC Comparison
Compare XERS & LINC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- LINC
- Stock Information
- Founded
- XERS 2005
- LINC 1946
- Country
- XERS United States
- LINC United States
- Employees
- XERS N/A
- LINC N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- LINC Other Consumer Services
- Sector
- XERS Health Care
- LINC Real Estate
- Exchange
- XERS Nasdaq
- LINC Nasdaq
- Market Cap
- XERS 444.0M
- LINC 507.8M
- IPO Year
- XERS 2018
- LINC 2005
- Fundamental
- Price
- XERS $3.09
- LINC $16.15
- Analyst Decision
- XERS Buy
- LINC Strong Buy
- Analyst Count
- XERS 3
- LINC 4
- Target Price
- XERS $4.87
- LINC $18.00
- AVG Volume (30 Days)
- XERS 1.9M
- LINC 132.5K
- Earning Date
- XERS 11-08-2024
- LINC 11-11-2024
- Dividend Yield
- XERS N/A
- LINC N/A
- EPS Growth
- XERS N/A
- LINC N/A
- EPS
- XERS N/A
- LINC 0.32
- Revenue
- XERS $187,361,000.00
- LINC $423,213,000.00
- Revenue This Year
- XERS $20.35
- LINC $15.35
- Revenue Next Year
- XERS $16.14
- LINC $9.30
- P/E Ratio
- XERS N/A
- LINC $50.49
- Revenue Growth
- XERS 22.72
- LINC 15.21
- 52 Week Low
- XERS $1.69
- LINC $8.78
- 52 Week High
- XERS $3.64
- LINC $18.74
- Technical
- Relative Strength Index (RSI)
- XERS 49.74
- LINC 67.17
- Support Level
- XERS $2.82
- LINC $14.82
- Resistance Level
- XERS $3.12
- LINC $18.74
- Average True Range (ATR)
- XERS 0.18
- LINC 0.86
- MACD
- XERS -0.03
- LINC -0.03
- Stochastic Oscillator
- XERS 32.93
- LINC 51.86
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About LINC Lincoln Educational Services Corporation
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services and business and information technology. Its reportable segments include; Campus Operations, and Transitional. Majority of the revenue is generated from Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.